Dark Blue Therapeutics

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

News

Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.